Literature DB >> 28320855

Salt Sensitivity of Angiogenesis Inhibition-Induced Blood Pressure Rise: Role of Interstitial Sodium Accumulation?

Stephanie Lankhorst1, David Severs1, Lajos Markó1, Natalia Rakova1, Jens Titze1, Dominik N Müller1, A H Jan Danser1, Anton H van den Meiracker2.   

Abstract

In response to salt loading, Na+ and Cl- accumulate in the skin in excess of water, stimulating skin lymphangiogenesis via activation of the mononuclear phagocyte system cell-derived vascular endothelial growth factor-C-vascular endothelial growth factor type 3 receptor signaling pathway. Inhibition of this pathway results in salt-sensitive hypertension. Sunitinib is an antiangiogenic, anticancer agent that blocks all 3 vascular endothelial growth factor receptors and increases blood pressure. We explored the salt dependency of sunitinib-induced hypertension and whether impairment of skin lymphangiogenesis is an underlying mechanism. Normotensive Wistar-Kyoto rats were exposed to a normal or high salt with or without sunitinib administration. Sunitinib induced a 15 mm Hg rise in telemetrically measured blood pressure, which was aggravated by a high-salt diet (HSD), resulting in a decline of the slope of the pressure-natriuresis curve. Without affecting body weight, plasma Na+ concentration or renal function, Na+ and Cl- skin content increased by 31% and 32% with the high salt and by 49% and 50% with the HSD plus sunitinib, whereas skin water increased by 17% and 24%, respectively. Skin mononuclear phagocyte system cell density increased both during sunitinib and a HSD, but no further increment was seen when HSD and sunitinib were combined. HSD increased skin lymphangiogenesis, while sunitinib tended to decrease lymphangiogenesis, both during a normal-salt diet and HSD. We conclude that sunitinib induces hypertension that is aggravated by high salt intake and not accompanied by impaired skin lymphangiogenesis.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  Na+ storage; angiogenesis inhibition; hypertension; lymphangiogenesis; salt sensitivity; sunitinib; vascular endothelial growth factor

Mesh:

Substances:

Year:  2017        PMID: 28320855     DOI: 10.1161/HYPERTENSIONAHA.116.08565

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  15 in total

Review 1.  Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition.

Authors:  Rhian M Touyz; Ninian N Lang; Joerg Herrmann; Anton H van den Meiracker; A H Jan Danser
Journal:  Hypertension       Date:  2017-06-19       Impact factor: 10.190

Review 2.  Management of VEGF-Targeted Therapy-Induced Hypertension.

Authors:  Stefano Caletti; Anna Paini; Maria Antonietta Coschignano; Carolina De Ciuceis; Matteo Nardin; Roberto Zulli; Maria Lorenza Muiesan; Massimo Salvetti; Damiano Rizzoni
Journal:  Curr Hypertens Rep       Date:  2018-06-29       Impact factor: 5.369

3.  Hemodynamics and Salt-and-Water Balance Link Sodium Storage and Vascular Dysfunction in Salt-Sensitive Subjects.

Authors:  Cheryl L Laffer; Robert C Scott; Jens M Titze; Friedrich C Luft; Fernando Elijovich
Journal:  Hypertension       Date:  2016-05-09       Impact factor: 10.190

Review 4.  Salt, Hypertension, and Immunity.

Authors:  A Justin Rucker; Nathan P Rudemiller; Steven D Crowley
Journal:  Annu Rev Physiol       Date:  2017-11-16       Impact factor: 19.318

Review 5.  Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.

Authors:  Arvind K Pandey; Eric K Singhi; Juan Pablo Arroyo; Talat Alp Ikizler; Edward R Gould; Jonathan Brown; Joshua A Beckman; David G Harrison; Javid Moslehi
Journal:  Hypertension       Date:  2017-12-26       Impact factor: 10.190

6.  DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.

Authors:  Sota Kato; Teisuke Takahashi; Noriyuki Miyata; Richard J Roman
Journal:  J Pharmacol Exp Ther       Date:  2019-12-04       Impact factor: 4.030

7.  Apatinib Through Activating the RhoA/ROCK Signaling Pathway to Cause Dysfunction of Vascular Smooth Muscle Cells.

Authors:  Wenjuan Wang; Qingjian He; Chenchen Zhuang; Haodong Zhang; Xin Fan; Qiongying Wang; Miaomiao Qi; Runmin Sun; Caie Li; Jing Yu
Journal:  Appl Biochem Biotechnol       Date:  2022-07-01       Impact factor: 3.094

8.  Research on the Mechanism and Prevention of Hypertension Caused by Apatinib Through the RhoA/ROCK Signaling Pathway in a Mouse Model of Gastric Cancer.

Authors:  Wenjuan Wang; Qingjian He; Caie Li; Chenchen Zhuang; Haodong Zhang; Qiongying Wang; Xin Fan; Miaomiao Qi; Runmin Sun; Jing Yu
Journal:  Front Cardiovasc Med       Date:  2022-06-23

9.  Tissue Sodium in Patients With Early Stage Hypertension: A Randomized Controlled Trial.

Authors:  Aseel Alsouqi; Serpil Muge Deger; Melis Sahinoz; Cindy Mambungu; Adrienne R Clagett; Aihua Bian; Andrew Guide; Thomas G Stewart; Mindy Pike; Cassianne Robinson-Cohen; Rachelle Crescenzi; Meena S Madhur; David G Harrison; Talat Alp Ikizler
Journal:  J Am Heart Assoc       Date:  2022-04-18       Impact factor: 6.106

10.  Inflammasome-Independent NALP3 Contributes to High-Salt Induced Endothelial Dysfunction.

Authors:  Hui Fu; Ji-Kuai Chen; Wen-Jie Lu; Yu-Jie Jiang; Yuan-Yuan Wang; Dong-Jie Li; Fu-Ming Shen
Journal:  Front Pharmacol       Date:  2018-08-22       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.